Aranesp is the trade name for Darbepoetin alfa, a synthetic version of erythropoietin, which stimulates the production of red blood cells. Aranesp has been used since its approval by the U.S. Food and Drug Administration (FDA) in 2001 to treat patients with anemia, as well as chronic renal failure. It has been frequently prescribed to individuals suffering anemia as a byproduct of chemotherapy.
The FDA has required black box warnings on all sales of Darbepoetin alfa in the United States, citing a number of potential adverse health risks, including:
- Myocardial infarction, or heart attack, as well as congestive heart failure
Hypertension (high blood pressure), with increased risk of stroke
- Venous thromboembolism
- Thrombosis of vascular access
- Tumor progression or recurrence
If you experienced side effects after being prescribed Aranesp, GetLegal has the tools and resources to help you find skilled legal representation to protect your rights. Visit our attorney directory, look for your geographic location and find the best lawyer for your situation.
Defective Drugs & Medical Devices Topics
Could You Be a U.S. Citizen and Not Know It?
Lately, the news is filled with stories of people like Peter Sean Brown: Brown, born in Philadelphia…Read More 05 Mar 2019, Tuesday
Common Law Marriage: Uncommon Arrangement, Common Concerns
During the past decade, there has been a great deal of debate over what does, and does not, count as…Read More 25 Feb 2019, Monday
New Revelations about Asbestos in Baby Powder
For years, mothers used talcum powder when changing their babies’ diapers. The sweet-smelling subs…Read More 18 Feb 2019, Monday